Please login to the form below

Not currently logged in
Email:
Password:

amyloid

This page shows the latest amyloid news and features for those working in and with pharma, biotech and healthcare.

Theranexus takes Alzheimer’s drug combo into clinic

Theranexus takes Alzheimer’s drug combo into clinic

While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid

Latest news

More from news
Approximately 12 fully matching, plus 129 partially matching documents found.

Latest Intelligence

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Examples of digital biomarker usage cases include:. Using an interactive app to pre-screen potential study participants; for instance, a game to assess cognitive ability as a predictor of beta-amyloid

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    All highly disappointing for Lilly (which saw its stock sink), for academics that backed the amyloid hypothesis and for patients. ... Professor Peter Roberts at the University of Bristol is one of those who feels that the amyloid card has been overplayed.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly's great hope in amyloid beta is now solanezumab, a candidate with a chequered history. ... I think Amyloid-beta will be a very powerful approach for early-stage disease, for delaying the onset of symptoms and their progression.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease. ... Alzheon's founder, president and chief executive officer Martin Tolar said: “ JP will provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics